IL280377A - Gene signatures to predict melanoma metastases and disease progression in the patient - Google Patents

Gene signatures to predict melanoma metastases and disease progression in the patient

Info

Publication number
IL280377A
IL280377A IL280377A IL28037721A IL280377A IL 280377 A IL280377 A IL 280377A IL 280377 A IL280377 A IL 280377A IL 28037721 A IL28037721 A IL 28037721A IL 280377 A IL280377 A IL 280377A
Authority
IL
Israel
Prior art keywords
melanoma
gene signatures
patient prognosis
predicting metastasis
metastasis
Prior art date
Application number
IL280377A
Other languages
English (en)
Hebrew (he)
Inventor
Meves Alexander
Bellomo Domenico
Original Assignee
Skylinedx B V
Mayo Found Medical Education & Res
Meves Alexander
Bellomo Domenico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skylinedx B V, Mayo Found Medical Education & Res, Meves Alexander, Bellomo Domenico filed Critical Skylinedx B V
Publication of IL280377A publication Critical patent/IL280377A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/686Polymerase chain reaction [PCR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/166Oligonucleotides used as internal standards, controls or normalisation probes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL280377A 2018-07-25 2021-01-24 Gene signatures to predict melanoma metastases and disease progression in the patient IL280377A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862703221P 2018-07-25 2018-07-25
US201862750294P 2018-10-25 2018-10-25
US201862778777P 2018-12-12 2018-12-12
PCT/NL2019/050487 WO2020022895A2 (en) 2018-07-25 2019-07-25 Gene signatures for predicting metastasis of melanoma and patient prognosis

Publications (1)

Publication Number Publication Date
IL280377A true IL280377A (en) 2021-03-25

Family

ID=68242821

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280377A IL280377A (en) 2018-07-25 2021-01-24 Gene signatures to predict melanoma metastases and disease progression in the patient

Country Status (11)

Country Link
US (2) US12473599B2 (https=)
EP (1) EP3827101B1 (https=)
JP (1) JP7633159B2 (https=)
KR (1) KR20210044233A (https=)
CN (1) CN113039289B (https=)
AU (1) AU2019310636B2 (https=)
CA (1) CA3107401A1 (https=)
DK (1) DK3827101T3 (https=)
ES (1) ES2966015T3 (https=)
IL (1) IL280377A (https=)
WO (1) WO2020022895A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102751357B1 (ko) * 2021-07-16 2025-01-06 한림대학교 산학협력단 구강암의 임프절 전이 예측과 관련된 유전자군
WO2023107329A1 (en) * 2021-12-08 2023-06-15 Mayo Foundation For Medical Education And Research Assessing and treating melanoma
AU2022406744A1 (en) * 2021-12-08 2024-07-11 Mayo Foundation For Medical Education And Research Assessing and treating melanoma
WO2024108191A1 (en) * 2022-11-18 2024-05-23 University Of Virginia Patent Foundation Machine learning approach to predicting lymph node metastases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040010045A1 (en) 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
AU2003298689A1 (en) 2002-11-21 2004-06-18 Wyeth Methods for diagnosing rcc and other solid tumors
US20070154889A1 (en) 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
US20060136145A1 (en) 2004-12-20 2006-06-22 Kuo-Jang Kao Universal reference standard for normalization of microarray gene expression profiling data
TW200719903A (en) 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms
NZ593226A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (efnb2) for colorectal cancer prognosis
WO2008021115A2 (en) 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
AU2007292219B2 (en) 2006-09-06 2014-04-24 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
AU2008247502A1 (en) 2007-05-04 2008-11-13 Dermtech International Diagnosis of melanoma by nucleic acid analysis
EP2191020A2 (en) 2007-08-16 2010-06-02 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
AU2009221778A1 (en) 2008-03-05 2009-09-11 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
US20120128667A1 (en) 2009-05-01 2012-05-24 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
AU2011305696A1 (en) 2010-09-20 2013-05-02 Advanced Cell Diagnostics, Inc. Biomarkers for differentiating melanoma from benign nevus in the skin
EP3195869B1 (en) 2012-07-27 2021-09-29 Agency for Science, Technology and Research (A*STAR) Method of promoting wound healing
WO2014077915A1 (en) 2012-11-14 2014-05-22 Mayo Foundation For Medical Education And Research Methods and materials for identifying malignant skin lesions
WO2016025717A1 (en) * 2014-08-14 2016-02-18 Mayo Foundation For Medical Education And Research Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer
TN2017000440A1 (en) 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
MX388345B (es) 2016-05-10 2025-03-19 Mayo Found Medical Education & Res Métodos y materiales para estadificar cáncer de piel y seleccionar tratamiento.

Also Published As

Publication number Publication date
CN113039289A (zh) 2021-06-25
US12473599B2 (en) 2025-11-18
JP7633159B2 (ja) 2025-02-19
EP3827101B1 (en) 2023-11-08
WO2020022895A2 (en) 2020-01-30
NZ771988A (en) 2025-02-28
AU2019310636B2 (en) 2025-06-26
DK3827101T3 (da) 2023-12-11
EP3827101A2 (en) 2021-06-02
ES2966015T3 (es) 2024-04-17
KR20210044233A (ko) 2021-04-22
US20260071281A1 (en) 2026-03-12
WO2020022895A3 (en) 2020-04-02
CA3107401A1 (en) 2020-01-30
US20210301353A1 (en) 2021-09-30
JP2021531831A (ja) 2021-11-25
CN113039289B (zh) 2025-11-07
AU2019310636A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
IL280377A (en) Gene signatures to predict melanoma metastases and disease progression in the patient
IL284400A (en) Polypeptides useful for gene editing and methods of use
ZA201608881B (en) Floating structure and method of installing same
EP3509947A4 (en) METHODS AND SYSTEMS FOR LIFTING AND LOWERING A PAYLOAD
GB202009760D0 (en) Data de-identification based on detection of allowable configurations for data de-indentification processes
IL276575A (en) BTK inhibitors and their mutants
GB201806064D0 (en) Improved Classification And Prognosis Of Prostate Cancer
SG11202006875VA (en) Biomarker predictive of tumour infiltrating lymphocyte therapy and uses thereof
IL291378A (en) Methods for filtering condensed matter related to specificity and their uses
EP3665981C0 (en) PROVISION AND USE OF INTERVALS FOR REFERENCE SIGNAL TIME DIFFERENCE MEASUREMENTS
EP3714623A4 (en) ACTIVATION OF SUPPORT FOR RELIABLE DATA SERVICE AND PS-DATA-OFF
GB2591194B (en) Modulation of gene expression and screening for deregulated protein expression
EP3798316A3 (en) Genes and gene signatures for diagnosis and treatment of melanoma
DK3231405T3 (da) Fremgangsmåde til at forudsige udskillelser og indretning hertil
IL288970A (en) Methods for detecting and predicting breast cancer
EP3774730A4 (en) CANCER METASTASIS INHIBITORS BY INHIBITING THE MIGRATION AND INVASION OF CANCER CELLS
SG11202104101TA (en) Method of detecting cancer and/or tuberculosis
HUE071053T2 (hu) Az alfa-V-béta-6 integrin gátlószerei
ZA202006927B (en) Systems and methods for predicting aspects of an unknown event
EP4265740A3 (en) Methods for predicting risk of metastasis in cutaneous melanoma
GB201812561D0 (en) Biomarkers and uses thereof
GB201806042D0 (en) Biomarkers and uses thereof
IL288045A (en) Cell-free mirna biomarkers for prognosis and diagnosis of neurodegenerative diseases
EP4372655C0 (en) PERSONAL AND SECURE DIGITAL ELECTRONIC ACCESS PERMISSION
GB201619808D0 (en) Biomarkers for the prognosis and diagnosis of cancer